The Primary Care Companion for CNS Disorders

CME Institute

Home | About Us | Mission Statement | All CME Activities | MyCME | CME Facebook | CME Twitter

JCP

Home | About JCP | Subscribe | Archive | Information for Authors | Information for Reviewers | Information for Advertisers | CNS Job Market | Customer Service | JCP Facebook | JCP Twitter

PCC

Home | About PCC | Register | Archive | Information for Authors | Information for Reviewers | PCC Facebook | PCC Twitter

Help

FAQ | About Psychiatrist.com | Terms of use | Privacy policy

magnifying glass for search

  • magnifying glass for search
  • Advanced Search

Login

Login  
Login | Login Help | Register | Subscribe
Register | Elerts

Quick Links

Font: A | A | A

Top

Purchase PDF

Vol 14, No 1
Table of Contents

Facebook ShareShare

twitter shareTweet This

envelope iconEmail a link

Related ►

Related Articles

[X]

<p class="frontmatter-fieldnotes disclaimernew" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms & Conditions</a>.</p> <div id="x11l01239">
<div class="story">
<p class="ltrs-br-ltr-br-title"><span class="bold">Antipsychotic-Induced Euprolactinemic Galactorrhea in an Adolescent Girl: A Case Report</span></p>
<p class="ltrs-br-ltr-br-body-text"><span class="semibold">To the Editor:</span> We describe a case report of galactorrhea with prolactin level within normal limits in a healthy 16-year-old African American girl after administration of quetiapine. Prolactin is an endogenous hormone from the anterior pituitary gland that promotes lactation. Dopamine predominantly inhibits prolactin. Antipsychotic medications block the dopamine-2 (D<span class="subscript">2</span>) receptor via the tuberoinfundibular dopamine pathway, which can result in hyperprolactinemia.<span class="htm-cite"><a href="#ref1">1</a></span> Serotonin is an indirect modulator of prolactin secretion.<span class="htm-cite"><a href="#ref2">2</a></span> Hyperprolactinemia can cause galactorrhea, gynecomastia, sexual dysfunction, menstrual irregularities, infertility, hirsutism, and acne in women due to hypoestrogenism; hypogonadism and impaired growth and sexual maturation in adolescents; and potential osteoporosis.<span class="htm-cite"><a href="#ref3">3</a>,<a href="#ref4">4</a></span> Women have greater prolactin elevations from antipsychotics than do men.<span class="htm-cite"><a href="#ref5">5</a>,<a href="#ref6">6</a></span> Children and adolescents may also have greater prolactin elevations in response to antipsychotics.<span class="htm-cite"><a href="#ref7">7</a></span> Conventional antipsychotics, risperidone, zotepine, and amisulpride are known to elevate prolactin more than other atypical antipsychotic medications.<span class="htm-cite"><a href="#ref4">4</a>,<a href="#ref8">8–10</a></span> The median time to onset of galactorrhea is 20 days (range, 7–75 days) after commencement of an antipsychotic medication.<span class="htm-cite"><a href="#ref8">8</a></span></p>
<p class="ltrs-br-ltr-br-body-text">Compared to typical antipsychotics with tighter D<span class="subscript">2</span> receptor binding, most atypical antipsychotics are less likely to cause hyperprolactinemia and thus galactorrhea. Quetiapine is known to have overall weaker dopamine binding activity; positron emission tomography scans showed transiently high striatal D<span class="subscript">2</span> receptor occupancy. Quetiapine’s transient association with the D<span class="subscript">2</span> receptor is postulated to allow normal dopaminergic neurotransmission in the tuberoinfundibular pathway and thus avoid hyperprolactinemia. This may explain only a temporary elevation of prolactin levels. D<span class="subscript">2</span> receptor occupancy decreases to 0%–27% in 12 hours.<span class="htm-cite"><a href="#ref11">11</a></span> Quetiapine is less likely to elevate serum prolactin levels than risperidone.<span class="htm-cite"><a href="#ref10">10</a>,<a href="#ref12">12</a></span></p>
<p class="ltrs-br-ltr-br-body-text">Fluoxetine also has been described to cause hyperprolactinemia and galactorrhea, possibly by stimulating prolactin release from pituitary lactotrophs.<span class="htm-cite"><a href="#ref13">13</a></span> Hyperprolactinemia and galactorrhea from selective serotonin reuptake inhibitor use tended to correlate with above average dosages.<span class="htm-cite"><a href="#ref14">14</a></span> Our patient was taking fluoxetine at 15 mg daily. Oral fluoxetine at 60 mg daily for 6 days increased prolactin levels in various studies.<span class="htm-cite"><a href="#ref14">14</a>,<a href="#ref15">15</a></span></p>
<p class="ltrs-br-ltr-br-body-text">&nbsp;</p>
<p class="ltrs-br-ltr-br-body-text"><span class="semibold-ital">Case report.</span><span class="semibold"> </span>Mary, a 16-year-old African American adolescent girl, presented to the adolescent inpatient unit in 2011 for a chief complaint of “hearing voices and seeing spirits that tell her to kill herself.” As a child, she had delays in meeting her milestones in walking, talking, and toileting. She denied any substance abuse history. Her urine drug screen was negative. Her medical history was unremarkable except for previous diagnosis of schizoaffective disorder.</p>
<p class="ltrs-br-ltr-br-body-text">Mary started hearing voices at 12 years of age. Previously, the voices commanded her to hurt others. She was in the 11th grade and receiving special education for behavior issues when she lost her grandfather and started hearing voices again. This time, the voices consisted of the voice of her deceased grandfather, the voice of her aunt, and an unidentified male voice. The voices were instructing her to kill herself now. She had multiple attempts of suicide by cutting herself. Sometimes, she “blacked out” in severe distress from the voices. She reported memory lapses and recalls poor choices and actions made during such episodes.</p>
<p class="ltrs-br-ltr-br-body-text">Her medications at admission included oral fluoxetine 10 mg daily and oral ziprasidone 60 mg twice daily. After reviewing her history, symptoms, and medication trials, we decided to treat her with oral fluoxetine 15 mg daily and oral quetiapine extended release (XR) 100 mg daily. Ziprasidone was discontinued because it was not effective. She reported bilateral mastalgia, breast enlargement, and “milk discharge” from her breasts 3 days after starting quetiapine. Galactorrhea was confirmed by physical examination. She denied having headaches and vision changes. Her serum prolactin level was 19.9 ng/mL (reference range is 3.4 to 24.1 ng/mL) 6 days after starting fluoxetine and quetiapine XR. Prolactin levels &gt;<span class="thinspace"> </span>100 ng/mL are characteristic of tumors secreting prolactin.<span class="htm-cite"><a href="#ref4">4</a></span> We checked her serum prolactin level on 2 different occasions; findings of both serum prolactin assays were not elevated beyond a normal reference range (reference range for a 13- to 15-year-old girl is &lt;<span class="thinspace"> </span>60 ng/mL<span class="htm-cite"><a href="#ref16">16</a>).</span> Both prolactin assays were obtained in a fasting state. Quetiapine XR was discontinued at this time. Her serum prolactin level was 19.2 ng/mL 7 days after stopping quetiapine XR. It can take 3 days to 3 weeks for serum prolactin levels to normalize after stopping antipsychotic medications.<span class="htm-cite"><a href="#ref4">4</a></span></p>
<p class="ltrs-br-ltr-br-body-text">Mary stated that her menstrual cycle was regular over the last 3 months. She did endorse vaginal discharge. The pelvic examination showed pelvic tenderness. Urinalysis confirmed elevated white blood cells and nitrites. We tested her for gonorrhea and chlamydia, and the results were negative. We treated her with doxycycline and azithromycin. Her urine culture was positive for diphtheroid bacilli. Her urine pregnancy test was negative, and her serum beta human chorionic gonadotropin test was also negative. Her thyroid-stimulating hormone and free T<span class="subscript">4</span> levels were within normal limits. Euprolactinemic galactorrhea has been associated with thyroid abnormalities.<span class="htm-cite"><a href="#ref17">17</a></span> Her blood urea and creatinine levels were within normal limits. Prolactin can be high in patients with chronic renal failure.<span class="htm-cite"><a href="#ref18">18</a></span> Gonadotropin-associated protein and acetylcholine have been identified as prolactin-inhibiting factors in animals.<span class="htm-cite"><a href="#ref19">19</a></span></p>
<p class="ltrs-br-ltr-br-body-text">A computed tomography scan of the head, performed after hospital discharge, showed no mass lesion in the brain. Mary exhibited hostile behavior and mood alterations with other females that were problematic. These behaviors can be a clinical manifestation of hyperprolactinemia,<span class="htm-cite"><a href="#ref20">20</a></span> but our patient had prolactin levels within normal limits. Quetiapine was discontinued, and after 2 weeks her galactorrhea resolved. Prolactin levels can be high in patients with chronic renal failure.<span class="htm-cite"><a href="#ref17">17</a></span> Her serum prolactin level was checked again 2 weeks after discontinuation of quetiapine, and it was still within the normal range.</p>
<p class="ltrs-br-ltr-br-body-text">&nbsp;</p>
<p class="ltrs-br-ltr-br-body-text">Drug-induced hyperprolactinemia is postulated to occur through various mechanisms. One mechanism decreases dopamine, another increases serotonin. Prolactin can be increased by various medications and mechanisms. Lithium acts on serotoninergic pathways to elevate prolactin. Estrogen potentiation of vasoactive intestinal peptide mediates hypothalamic synthesis of prolactin. Estrogen also has actions on the pituitary lactotroph cells to stimulate prolactin release. Opiates can inhibit dopamine synthesis and raise prolactin. H<span class="subscript">2</span> antagonists can inhibit dopamine release. Alprazolam raises prolactin levels through an unclear mechanism. Most psychotropic medications increase prolactin by inhibiting dopaminergic pathways.<span class="htm-cite"><a href="#ref2">2</a>,<a href="#ref4">4</a></span> Thyrotropin-releasing hormone promotes prolactin release.<span class="htm-cite"><a href="#ref21">21</a></span></p>
<p class="ltrs-br-ltr-br-body-text">There is a trend to apply atypical antipsychotics to treat a broad spectrum of psychiatric diseases. Quetiapine has a lower affinity for dopamine D<span class="subscript">2</span> receptors and appears to be selective for mesolimbic and mesocortical dopamine receptors, with relative sparing of the tuberoinfundibular system.<span class="htm-cite"><a href="#ref22">22</a></span> Quetiapine has also been used to correct olanzapine-induced galactorrhea.<span class="htm-cite"><a href="#ref23">23</a></span> However, there is a case report documenting dose-dependent quetiapine-induced galactorrhea.<span class="htm-cite"><a href="#ref24">24</a></span> Female adolescents are more vulnerable to the side effect of galactorrhea caused by antipsychotic medications. In this case, typical and atypical antipsychotic medications most likely contributed to the galactorrhea, although fluoxetine may have contributed as well. Our patient had a serum prolactin level within normal limits despite the galactorrhea. Our patient was reluctant to reveal that she had galactorrhea; clinicians should screen female adolescents for galactorrhea when prescribing psychotropic medications and administer atypical antipsychotics cautiously.</p>
<p class="ltrs-br-ltr-br-references-head"><span class="smallcaps">References</span></p>
<p class="references-references-text-1-9"><a name="ref1"></a>1. Petty RG. Prolactin and antipsychotic medications: mechanism of action. <span class="italic">Schizophr Res</span>. 1999;35(suppl 1):S67–S73. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10190227&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1016/S0920-9964(98)00158-3">doi:10.1016/S0920-9964(98)00158-3</a></span></p>
<p class="references-references-text-1-9"><a name="ref2"></a>2. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics—a review. <span class="italic">Hum Psychopharmacol</span>. 2010;25(4):281–297. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20521318&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1002/hup.1116">doi:10.1002/hup.1116</a></span></p>
<p class="references-references-text-1-9"><a name="ref3"></a>3. Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. <span class="italic">J&nbsp;Child Adolesc Psychopharmacol</span>. 2004;14(3):359–371. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15650493&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1089/cap.2004.14.359">doi:10.1089/cap.2004.14.359</a></span></p>
<p class="references-references-text-1-9"><a name="ref4"></a>4. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. <span class="italic">Drugs</span>. 2004;64(20):2291–2314. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15456328&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.2165/00003495-200464200-00003">doi:10.2165/00003495-200464200-00003</a></span> <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8776743&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1159/000119265">doi:10.1159/000119265</a></span></p>
<p class="references-references-text-1-9"><a name="ref5"></a>5. Wode-Helgodt B, Eneroth P, Fyrö B, et al. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. <span class="italic">Acta Psychiatr Scand</span>. 1977;56(4):280–293. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=335789&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1111/j.1600-0447.1977.tb00229.x">doi:10.1111/j.1600-0447.1977.tb00229.x</a></span></p>
<p class="references-references-text-1-9"><a name="ref6"></a>6. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. <span class="italic">Clin Exp Pharmacol Physiol</span>. 1992;19(9):603–606. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1356671&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1111/j.1440-1681.1992.tb00511.x">doi:10.1111/j.1440-1681.1992.tb00511.x</a></span></p>
<p class="references-references-text-1-9"><a name="ref7"></a>7. Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. <span class="italic">J&nbsp;Child Adolesc Psychopharmacol</span>. 1999;9(4):239–245. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10630453&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1089/cap.1999.9.239">doi:10.1089/cap.1999.9.239</a></span></p>
<p class="references-references-text-1-9"><a name="ref8"></a>8. Windgassen K, Wesselmann U, Schulze Mönking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. <span class="italic">Neuropsychobiology</span>. 1996;33(3):142–146.</p>
<p class="references-references-text-1-9"><a name="ref9"></a>9. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. <span class="italic">J&nbsp;Clin Psychopharmacol</span>. 1999;19(1):57–61. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9934944&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1097/00004714-199902000-00011">doi:10.1097/00004714-199902000-00011</a></span></p>
<p class="references-references-text-10-99"><a name="ref10"></a>10. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. <span class="italic">Cochrane Database Syst Rev</span>. 2011;1(1):CD006626. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21249678&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref11"></a>11. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. <span class="italic">Arch Gen Psychiatry</span>. 2000;57(6):553–559. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10839333&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1001/archpsyc.57.6.553">doi:10.1001/archpsyc.57.6.553</a></span></p>
<p class="references-references-text-10-99"><a name="ref12"></a>12. Swadi HS, Craig BJ, Pirwani NZ, et al. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. <span class="italic">Int Clin Psychopharmacol</span>. 2010;25(1):1–6. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19809337&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1097/YIC.0b013e3283320511">doi:10.1097/YIC.0b013e3283320511</a></span></p>
<p class="references-references-text-10-99"><a name="ref13"></a>13. Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. <span class="italic">Mayo Clin Proc</span>. 2001;76(2):215–216. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11213313&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.4065/76.2.215">doi:10.4065/76.2.215</a></span></p>
<p class="references-references-text-10-99"><a name="ref14"></a>14. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. <span class="italic">Drug Saf</span>. 1999;20(3):277–287. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10221856&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.2165/00002018-199920030-00007">doi:10.2165/00002018-199920030-00007</a></span></p>
<p class="references-references-text-10-99"><a name="ref15"></a>15. Urban RJ, Veldhuis JD. A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. <span class="italic">Am J Obstet Gynecol</span>. 1991;164(1, pt 1):147–152. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1986602&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref16"></a>16. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. <span class="italic">J&nbsp;Clin Psychiatry</span>. 2008;69(suppl 1):32–44. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18484806&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref17"></a>17. Ataya KM, Subramanian MG, Lawson DM, et al. Euprolactinemic galactorrhea: response of bioassayable prolactin to thyrotropin-releasing hormone. <span class="italic">J&nbsp;Reprod Med</span>. 1996;41(3):156–160. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8778412&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref18"></a>18. Sievertsen GD, Lim VS, Nakawatase C, et al. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. <span class="italic">J&nbsp;Clin Endocrinol Metab</span>. 1980;50(5):846–852. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7372775&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1210/jcem-50-5-846">doi:10.1210/jcem-50-5-846</a></span></p>
<p class="references-references-text-10-99"><a name="ref19"></a>19. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. <span class="italic">Physiol Rev</span>. 2000;80(4):1523–1631. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11015620&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref20"></a>20. Fava M, Fava GA, Kellner R, et al. Psychosomatic aspects of hyperprolactinemia. <span class="italic">Psychother Psychosom</span>. 1983;40(1–4):257–262. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6657880&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1159/000287773">doi:10.1159/000287773</a></span></p>
<p class="references-references-text-10-99"><a name="ref21"></a>21. Jackson IM. Thyrotropin-releasing hormone. <span class="italic">N Engl J Med</span>. 1982;306(3):145–155. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6798440&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.1056/NEJM198201213060305">doi:10.1056/NEJM198201213060305</a></span></p>
<p class="references-references-text-10-99"><a name="ref22"></a>22. Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. <span class="italic">Drugs Today (Barc)</span>. 1999;35(3):193–210. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12973385&dopt=Abstract">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref23"></a>23 Kingsbury SJ, Castelo C, Abulseoud O. Quetiapine for olanzapine-induced galactorrhea. <span class="italic">Am J Psychiatry</span>. 2002;159(6):1061.<span class="pubmed-crossref"> <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kingsbury%20SJ%252C%20Castelo%20C%252C%20Abulseoud%20O">PubMed</a></span></p>
<p class="references-references-text-10-99"><a name="ref24"></a>24. Sethi S, Sharma M, Malik A. Dose-dependent galactorrhea with quetiapine. <span class="italic">Indian J Psychiatry</span>. 2010;52(4):371–372. <span class="pubmed-crossref"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21267374&dopt=Abstract">PubMed</a> <a href="http://dx.doi.org/10.4103/0019-5545.74315">doi:10.4103/0019-5545.74315</a></span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Woo Jin Kwak, DO</span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Ankit Patel, MD</span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Fasiha Haq, MD</span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Fatima Siddiqui, MD</span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Mohammad Younis, MD</span></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Shakeel Raza, MD</span></p>
<p class="ltrs-br-ltr-br-author"><a href="mailto:shakeeldr@yahoo.com">shakeeldr@yahoo.com</a></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Radhika Gholkar, MD</span></p>
<p class="ltrs-br-ltr-br-endmatter-fieldnotes"><span class="semibold-ital">Author affiliations:</span><span class="semibold"> </span>Department of Psychiatry, University of South Alabama, Mobile. </p>
<p class="ltrs-br-ltr-br-endmatter-fieldnotes"><span class="semibold-ital">Potential conflicts of interest: </span>None reported.</p>
<p class="ltrs-br-ltr-br-endmatter-fieldnotes"><span class="semibold-ital">Funding/support: </span>None reported.</p>
<p class="ltrs-br-ltr-br-endmatter-fieldnotes"><span class="semibold-ital">Published online:</span> February 2, 2012.</p>
<p class="ltrs-br-ltr-br-copyright-doi"><span class="italic">Prim Care Companion CNS Disord 2012:14(1):</span><span class="doi">doi:10.4088/PCC.11l01239</span></p>
<p class="ltrs-br-ltr-br-copyright-doi"><span class="italic">© Copyright 2012 Physicians Postgraduate Press, Inc.</span></p>
</div>
</div>
Manage Subscriptions
/_layouts/images/ReportServer/Manage_Subscription.gif
/PCC/article/_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}
0x80
0x0
FileType
rdl
350
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
351
Manage Shared Datasets
/PCC/article/_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
352
Manage Parameters
/PCC/article/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
353
Manage Processing Options
/PCC/article/_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
355
View Report History
/PCC/article/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}
0x0
0x40
FileType
rdl
356
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
350
Edit Data Source Definition
/PCC/article/_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
351
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports
/PCC/article/_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
352
Manage Model Item Security
/PCC/article/_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}
0x0
0x2000000
FileType
smdl
353
Regenerate Model
/PCC/article/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
354
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
smdl
351
Load in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}
0x0
0x2
FileType
smdl
250
Edit in Report Builder
/_layouts/images/ReportServer/EditReport.gif
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
250
Edit in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
250
Manage Caching Options
/PCC/article/_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true
0x0
0x4
FileType
rsd
351
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rsd
352
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;
0x0
0x1
ContentType
0x01
898
Document Set Version History
javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
330
Send To other location
javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
350

Information Links

Terms of Use | Privacy Policy | Information for Authors (JCP) | Information for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers | Media Relations | PPP COVID-19 Statement

Help

Contact us | Unsubscribe from Elerts | Customer Service | FAQ | About JCP | About PCC | About Psychiatrist.com

Our Family of Sites

Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute | Strong Veterans
Anonymous